To examine the drivers of innovation, this paper studies the global R&D effort to fight the deadliest diseases and presents four results. We find: (1) global pharmaceutical R&D activity - measured by clinical trials - typically follows the 'law of diminishing efforts': i.e. the elasticity of R&D...

This paper explores the possible job creation effect of innovation activity. We analyze a unique panel dataset covering almost 20,000 patenting firms from Europe over the period 2003-2012. The main outcome from the proposed GMM-SYS estimations is the labour-friendly nature of innovation, which...

If redistribution is distortionary, and if the income of skilled workers is due to knowledgeintensive activities and depends positively on intellectual property, a social planner which cares about income distribution may in principle want to use a reduction in Intellectual Property Rights (IPRs)...

Teamwork in research has been on the rise and so has the size of R&D teams. This paper offers an explanation for increasing team size that we call the "racing against time" hypothesis: With innovation races more competitive globally, R&D firms need to finish research projects as quickly as...

We study the evolution of patenting in China from 1985-2019. We use a Large Language Model to measure patent importance based on patent abstracts and classify patent ownership using a comprehensive business registry. We highlight four insights. First, average patent importance declined from...

The launch of Viagra in April 1998 led to a historically unprecedented high usage of erectile dysfunction (ED) drugs. We test whether Viagra's introduction significantly influenced outcomes for its target population such as STD rates of older men, as well as its non-target populations, such as...

This study is an empirical assessment of the impact of the drug decriminalization policy followed by Portugal in July, 2001. We investigate especially the impact of the policy change on the price of illicit drugs. The analysis is performed using a difference-in-differences approach and a...

What makes prescription drugs cost so much? The media and Congress say it is corporate greed, while pharmaceutical firms blame federal regulations and an expensive drug development process. This study focuses on R & D (R&D) expenditures at global pharmaceutical firms and explores the driving...

In response to the epidemic of prescription-drug abuse, now 49 US states have passed legislation to establish Prescription Drug Monitoring Programs (PDMPs). These programs track controlled-substance prescribing and usage behavior in an effort to improve patient outcomes and identify and preempt...